ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in the United States.

Addressing Gaps in Influenza Prevention

Seasonal vaccination remains central to influenza prevention. However, changes in circulating influenza viruses and variability in individual immune response can limit vaccine protection, particularly among older adults and people who are immunocompromised. Additional preventive approaches could help address these unmet needs.

According to the U.S. Centers for Disease Control and Prevention (CDC), despite the availability of influenza vaccines, the 2025–2026 influenza season resulted in at least 32 million illnesses, 380,000 hospitalizations and 24,000 deaths in the United States.

About AK0406

AK0406 is a novel AFC drug discovered and developed by ArkBio. By precisely conjugating multiple potent small-molecular antivirals to an antibody Fc domain, AK0406 is designed to combine direct antiviral activity with Fc-mediated immune clearance to prevent influenza, with potential therapeutic applications.

In preclinical studies, AK0406 demonstrated broad-spectrum and highly potent antiviral activity against both influenza A and B strains. It has also been optimized for its pharmacokinetics (PK) properties and GMP manufacturing process.

Global Clinical Development

In February 2026, AK0406 received approval from a Human Research Ethics Committee (HREC) in Australia to initiate a phase I clinical trial. In July 2026, ArkBio announced that enrollment and dosing of healthy adult participants had been completed across all cohorts and that the study had entered the follow-up phase.

In August 2026, National Medical Products Administration (NMPA) of China cleared the IND application for AK0406 for influenza prevention. The FDA clearance marks a further milestone in the global clinical development of AK0406.

Planned U.S. Phase II Trial

The U.S. phase II clinical trial will be a multicenter, randomized, double-blind, placebo-controlled study in adults during an influenza season. Its primary objective is to evaluate AK0406 for influenza prevention. The study will also assess safety, tolerability, PK and immunogenicity. The resulting data will inform AK0406's future global development strategy.

ArkBio plans to continue discussions with the FDA and the Center for Drug Evaluation (CDE) of China's NMPA to advance phase II development in the United States and China. Through parallel development pathways, the company aims to accelerate the AK0406 program as an additional option for influenza prevention, addressing challenges posed by viral evolution and limited vaccine protection, including in populations at high-risk of severe disease.

About ArkBio

ArkBio is a commercial-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for treatment of respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated innovative R&D pipeline through internal innovation and strategic collaborations.

Key R&D pipeline assets include: ziresovir (AK0529), the first direct-acting antiviral for RSV with positive phase III results; AK3280, a potentially best-in-class anti-fibrotic agent with positive phase II results for treatment of idiopathic pulmonary fibrosis, currently in a phase III trial; AK0901, approved and commercialized in China for ADHD treatment. The company also has multiple first-in-class or best-in-class innovative drug candidates under clinical or preclinical development.

ArkBio has established strategic partnerships with multinational and domestic pharmaceutical companies including Roche, Genentech, and Qilu Pharmaceutical; leading academic institutions including The Scripps Research Institute and the Institute of Microbiology, Chinese Academy of Sciences; and other domestic and international biotech companies and CROs.

For more information, please visit: www.arkbiosciences.com

Investor Inquiries: [email protected]

SOURCE Arkbio

Share this article

LONDON, Oct. 12, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP continues to grow its London Energy & Natural Resources Practice with the addition of Hannah Roscoe as a shareholder. Roscoe advises clients across the energy and infrastructure sectors on mergers and acquisitions (M&A), joint ventures, commercial arrangements, restructurings, financings, and project development.

Roscoe's arrival follows the recent addition of Sofiya Bumagin, who joined Greenberg Traurig's London Energy & Natural Resources Practice from Sidley Austin. The two hires add complementary transactional capabilities to the firm's London offering, with Roscoe advising on energy M&A, project development, and commercial matters, and Bumagin focusing on infrastructure M&A and investments for private equity firms and other private capital providers.

Greenberg Traurig Executive Chairman Richard A. Rosenbaum said: "The firm's strategic focus on energy and infrastructure across the globe is in part driven by the continued growth and excellence of our London team. Hannah's arrival is another example of our investment in leading talent in these important sectors. She brings a strong track record across M&A, project development, and financing. Together with the addition of Sofiya Bumagin, her arrival further strengthens our ability to support clients on complex energy and infrastructure matters across jurisdictions."

Roscoe's experience includes battery storage transactions, biomass plant restructurings, and matters relating to green hydrogen. Recent mandates include a landmark financing of a synchronous condenser portfolio, the sale of an onshore wind farm, acquisitions involving battery storage units, and the restructuring of highway businesses.

Executive Vice President and London Managing Shareholder Fiona Adams said: "Hannah's arrival is an important addition to our London platform and reflects the breadth of experience we are continuing to develop across energy and infrastructure. Her practice covers many of the areas where clients are navigating investment and change, from energy transition and infrastructure development to M&A and restructuring. Alongside Sofiya's private capital and infrastructure investment experience, Hannah adds another dimension to the transactional capabilities we can offer clients from London and through our global network."

Roscoe will work closely with London Energy Practice Head Shashank Krishna, advising investors and other market participants on energy and infrastructure transactions in the UK and internationally.

Krishna added: "Hannah brings broad experience across energy and infrastructure transactions, from M&A to project development and financings. Her sector knowledge and commercial perspective are highly complementary to the work already being developed in London, and her arrival gives us greater depth across energy and infrastructure transactions, from investment and development through to restructuring and other strategic matters. We look forward to working with Hannah as we continue to build our energy and infrastructure capabilities in London and globally."

Roscoe said: "Greenberg Traurig has developed an impressive international platform with deep capabilities across energy and infrastructure, including M&A and private capital. The opportunity to join the firm as it continues to invest in its London practice was particularly attractive. I look forward to working with Shashank and colleagues across the firm's global network on strategic transactions, investments, and projects."

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

SOURCE Greenberg Traurig, LLP

Share this article

GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration

Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution

SEOUL, South Korea and RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that it signed a Memorandum of Understanding (MOU) with LabConnect on October 12 to expand global clinical trial collaboration. LabConnect is a global central laboratory and clinical trial samples solutions partner.

Built on a collaborative relationship spanning more than 20 years, this agreement aims to improve the operational efficiency of global clinical trial projects by linking the regional capabilities and expertise of both companies across North America and the Asia-Pacific (APAC) region.

The signing ceremony, held at GCCL's headquarters, was attended by key executives from both organizations, including GCCL CEO Kwan-goo Cho and from LabConnect, Jeff Mayhew, Founder and Strategic Commercial Advisor, and Joshua Gentile, Senior Vice President, Head of Commercial Sales and Marketing. During the event, the two companies shared their core services and future visions, discussing key collaborative initiatives, including:

- Identifying potential clients and supporting sales within each region

- Integrating global clinical trials and central laboratory services

- Cooperating on project management and client communications

- Formulating joint marketing strategies and identifying new business opportunities

Under this agreement, GCCL and LabConnect plan to establish a mutual collaboration framework leveraging their respective regional strengths and partner relationships. Furthermore, the companies intend to drive joint sales and marketing initiatives while setting up shared systems and processes for client responses and project management.

"Through this collaboration with GCCL, we expect to simplify and orchestrate complex studies conducted in South Korea and the Asia-Pacific region," said Jeff Mayhew, Founder and Strategic Commercial Advisor of LabConnect. "Pairing GCCL's laboratory and logistics strength with our global alliance of clinical and specialty laboratories, along with proactive sample logistics oversight and intervention, provides sponsors a more coordinated path for multi-regional studies."

Kwan-goo Cho, CEO of GCCL, stated, "This MOU marks the starting point of connecting GCCL's execution capabilities in the APAC region with LabConnect's comprehensive global alliance of clinical and specialty laboratories. We are committed to building a practical collaborative framework spanning joint sales, project execution, and client management to accelerate our global clinical trial business."

About LabConnect

LabConnect® is a global central laboratory services and clinical trial sample solutions partner, connecting the full sample journey, from biomarker strategy and custom kitting through testing, storage, and submission-ready data. The company combines scientific and operational expertise, its global alliance of clinical and specialty laboratories, worldwide logistics oversight, and integrated data services to support routine and specialized testing across complex global studies. LabConnect helps pharmaceutical, biotechnology, and contract research organizations reduce operational risk, improve study predictability, and generate meaningful insights from each sample. Visit LabConnect.com.

About GCCL

GCCL, a subsidiary of the GC Group, is a leading clinical trial sample analysis provider offering an integrated "one-stop lab solution" with central, bioanalysis, and BSL-3 labs under one system. With tailored solutions, GCCL delivers precise and efficient analytical services across all phases of clinical trials, solidifying its position as a trusted partner in new drug development. Leveraging advanced platforms and LIMS, the company supports partners across Asia and beyond with customized and compliant solutions. In recognition of its leadership, GCCL recently received Frost & Sullivan's 2025 Best Practices Customer Value Leadership Award in the Asia-Pacific clinical sample analysis services industry.

SOURCE LabConnect

Share this article

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

If you are a long-term EXEL stockholder please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Kuehn Law, PLLC

Justin Kuehn, Esq.

53 Hill Street, Suite 605

Southampton, NY 11968

[email protected]

(833) 672-0814

SOURCE Kuehn Law, PLLC

Share this article

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Option Care Health, Inc. (NASDAQ: OPCH)'s sale to CD&R, McKesson Corporation for $32.05 per share. If you are an Option Care shareholder, click here to learn more about your rights and options.

Pacira BioSciences, Inc. (NASDAQ: PCRX)'s sale to Viatris Inc. for $36.50 per share in cash. If you are a Pacira shareholder, click here to learn more about your rights and options.

RXO Inc. (NYSE: RXO)'s sale to C.H. Robinson Worldwide, Inc. for $17.25 per share in cash and 0.0856 shares of C.H. Robinson common stock for each RXO share. Upon closing of the Proposed Transaction, RXO shareholders are expected to own 11% of the combined company. If you are a RXO shareholder, click here to learn more about your legal rights and options.

Boundless Bio, Inc. (NASDAQ: BOLD)'s merger with Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company. If you are a Boundless Bio shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLC

Daniel Sadeh, Esq.

Zachary Halper, Esq.

One World Trade Center

85th Floor

New York, NY 10007

(212) 763-0060

[email protected]

[email protected]

https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Share this article

Aeon joins Austin's leading deep tech companies following major defense contract awards, production milestones, and expansion of its manufacturing operations.

AUSTIN, Texas, Oct. 12, 2026 /PRNewswire/ -- Aeon Industrial, a vertically integrated defense manufacturer developing advanced missile systems, interceptors, and critical defense subsystems, has been named to the inaugural 2026 Austin Deep Tech 50, a list recognizing companies driving innovation and industrial growth in Central Texas.

The list was organized by Overmatch Ventures in partnership with seven leading venture capital firms: Valor Equity Partners, 8VC, Banner VC, B Capital, Ambition Capital, Ensemble VC, and Trust Ventures. The Austin Deep Tech 50 recognizes 50 of the region's most promising deep technology companies, highlighting the firms advancing critical technologies and shaping the next generation of American industry.

Aeon's selection follows a series of major milestones as the company expands its defense manufacturing capabilities and scales production for the U.S. military, allied nations, and defense industry customers. The company also delivered ahead of schedule on a complex U.S. Army contract involving the development of an all-up weapon system and warhead, as well as successful live testing.

In recent weeks, Aeon has secured a key eight-figure defense contract, placed more than 10,000 of its MERC high-voltage electronic safe-and-arm devices into production following successful performance at the Department of War's Drone Dominance initiative, and earned selection in the U.S. Army's interceptor challenge with its layered air and missile defense architecture.

"America needs a defense industrial base capable of producing advanced weapons at the scale and cost required to meet today's threats," said Naweed Tahmas, Founder and CEO of Aeon Industrial. "We're building that capability here in Austin. Being recognized for advancing American manufacturing and deep technology is a testament to our team and the industrial ecosystem taking shape in Texas."

Aeon is expanding production at its new 140,000-square-foot manufacturing facility in Cedar Park, Texas, just outside Austin. The facility brings missile systems, interceptors, propulsion, fuzing, software, and assembly under one roof, enabling Aeon to manufacture complete weapon systems and critical subsystems at industrial scale for government and industry customers.

Aeon's core portfolio includes Zeus, a lightweight, software-defined tactical missile system designed for shoulder-fired use and integration across ground, air, and maritime platforms. Zeus features interchangeable sensors and warheads, enabling a single system to address a wide range of threats, from drones to armored vehicles. The company also manufactures MERC, a low-cost, high-voltage electronic safe-and-arm device supporting time, proximity, and impact fuzing across drones, missiles, and interceptors. Both products are designed for affordability, scalability, and high-volume production.

Aeon's vertically integrated manufacturing model is designed to reduce costs, accelerate production timelines, and deliver affordable mass to the U.S. military, allied nations, and defense industry customers.

About Aeon Industrial

Aeon Industrial is a vertically integrated defense manufacturer developing and producing advanced strike systems and critical subsystems at industrial scale. From its 140,000-square-foot manufacturing facility, Aeon brings weapon design and production under one roof, including propulsion, fuzing, autonomy and other critical subsystems. Led by former special operators, senior government officials and experienced aerospace and defense engineers, Aeon is a trusted partner to U.S. government customers and industry.

SOURCE Aeon Industrial

Share this article

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

If you are a long-term IMVT stockholder please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. The consultation and case are free with no obligation to you.Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Kuehn Law, PLLC

Justin Kuehn, Esq.

53 Hill Street, Suite 605

Southampton, NY 11968

[email protected]

(833) 672-0814

SOURCE Kuehn Law, PLLC

Share this article

Costco members can now purchase the flagship smartphone gimbal online for $199.99, with AI tracking and touchscreen remote control for everyday filming.

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Hohem, a global pioneer in intelligent imaging, today announced that its flagship iSteady M7 AI tracking smartphone gimbal is available on Costco.com at a Costco member-only price of $199.99, compared with its U.S. MSRP of $299. The launch marks Hohem's first entry into U.S. membership retail, bringing its AI filming tools to one of the country's largest retailers.

"We're excited to partner with Costco in the U.S., a premier national membership retailer, to bring Hohem's latest AI tracking and stabilization technology to its members," said Chen Min, CEO of Hohem. "Costco's commitment to delivering quality products at exceptional value aligns closely with our belief that innovative filming tools should be accessible to more people. Bringing the iSteady M7 to Costco.com combines advanced technology with compelling member value, making it easier for members to capture family moments, document their travels, or create content with confidence. We look forward to building on this partnership and bringing more innovation to Costco members."

The iSteady M7 supports filming needs ranging from family celebrations and trips to travel vlogs, product demos and livestreams. Key features include:

- AI Tracking Across Camera Apps: The on-device AI tracker follows people, pets and other subjects while users film with their phone's native camera or livestreaming apps, without requiring a dedicated tracking app.

- Detachable Touchscreen Remote: The 1.4-inch touchscreen displays a live view from the AI tracker, lets users select tracking subjects by tapping or dragging, and provides remote control of the gimbal—making it easier to film independently or step into the shot.

- More Flexible Shooting Angles: A built-in extension pole helps users explore high and low angles, from filming above a crowd to capturing a pet's-eye view.

- iSteady 9.0 Stabilization: Three-axis stabilization helps reduce shake while walking or filming on the move, while 360° infinite pan rotation provides more freedom for tracking shots and camera movements.

- Support for Expanded Smartphone Setups: A payload capacity of up to 500g and accessory mounting options accommodate compatible smartphones and additional filming equipment, such as microphones, phone lenses and fill lights.

The iSteady M7 (Costco Item 2091049) is now available on Costco.com at a Costco member-only price of $199.99.

About Hohem

Founded in 2014, Hohem is a global pioneer in intelligent imaging that makes great filming effortless, so everyone can make moments, from everyday storytellers to seasoned creators. Hohem pioneered the first on-device AI tracking on a smartphone gimbal in 2021 and has since grown from stabilization into a full imaging lineup, from phone and camera gimbals to gimbal cameras, made to capture life anywhere. Its award-winning products reach 5 million+ users in 70+ countries through leading retailers and online. To learn more, visit www.hohem.com.

SOURCE Hohem

Share this article

With more than 90 employees across 13 states, backing from M33 Growth, and a growing roster of multi-unit brands, the restaurant technology company celebrates its new home with a Grand Opening on Thursday, October 15, 2026

KANSAS CITY, Mo., Oct. 12, 2026 /PRNewswire/ -- Rosnet, the restaurant data and operations platform trusted by 84 franchise brands across more than 6,000 locations, is officially out of the cave. For years, the company worked out of an underground business park carved into the limestone bluffs of Parkville, Missouri. Now it has moved into a modern, purpose-built headquarters at 11500 N Ambassador Drive, Suite 400, in Kansas City's Northland.

The move isn't just a change of address. It's what growth looks like when you can see it. Over the past year Rosnet has added clients, expanded its team, strengthened its leadership bench, and secured new investment. The cave served the company well for years, but this next phase of growth called for a workplace built for in-person collaboration.

A bigger team. Rosnet now employs more than 90 people across 13 states, with Kansas City as the hub. The company has also strengthened its leadership team in 2026, led by CEO Derek Slayton, to guide its next phase of expansion.

More operators are on the platform. Rosnet's reporting, food management, and labor management tools now support 84 franchise brands and more than 6,000 restaurant locations.

Serious investment behind it. Rosnet is backed by M33 Growth, which completed a majority investment in the company earlier this year. We believe that partnership gives Rosnet the fuel to scale faster than at any other point in its history.

Built for being together. The new fourth-floor space was designed around in-person collaboration, supporting Rosnet's return-to-office program that launched in September. It features a training and conference room that seats up to 87 with full AV, huddle rooms outfitted for hybrid meetings, whiteboards in every room, two full kitchens, and an on-site micro market stocked with fresh food and snacks. There is also a game room for friendly competition and a well-earned break between meetings. Coffee is on the house.

Every room has a KC story. Conference rooms are named for Kansas City landmarks and neighborhoods: Boulevard, Union Station, Parkville, Northland, Legends, and Crossroads. The Parkville room is a nod to the company's longtime home, and the rest are a love letter to the city Rosnet has called home for more than 25 years. Meetings in the Boulevard room may or may not end with a toast.

"We loved the cave, but you can only fit so much growth underground," said Derek Slayton, CEO of Rosnet. "This space is a reflection of where Rosnet is headed. We're adding clients, adding talent, and investing in the kind of culture you can only build when people are in the same room solving problems together. Our clients run restaurants where teamwork happens face to face every shift, and we want our team to work the same way. Kansas City has been home for more than 25 years, and this headquarters is our commitment to growing here for a long time to come."

Come see it for yourself. Rosnet will celebrate a Grand Opening event on Thursday, October 15th at 11500 N Ambassador Drive, Suite 400, Kansas City, MO 64153. Members of the media are invited to tour the space, meet the team, and grab a seat in the Union Station room. To RSVP, contact Erin Neuburger at [email protected].

About Rosnet: Founded in 1998, Rosnet has grown into a respected leader in the restaurant data and operations marketplace. Thousands of locations, including large multi-unit concepts like Applebee's, Wendy's, Corner Bakery, STK, and IHOP, utilize the company's reporting, food management, and labor management systems. Rosnet couples easy-to-use tools with world-class support to help restaurant companies maximize profits without the need to invest in multiple systems. Learn more at www.rosnet.com.

SOURCE Rosnet

Share this article

CME Group's Corn Futures Set New Daily Volume Record After USDA Raised Outlook

CHICAGO, Oct. 12, 2026 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that its Corn futures reached a new daily volume record of 1,206,376 contracts on October 9, surpassing the previous record of 1,128,597 contracts traded on March 29, 2019.

"Following last week's surprise USDA report, market participants turned to our Corn futures to quickly adjust positions and manage price risk," said John Ricci, Global Head of Agricultural Products. "The market had priced in lower yields after a challenging summer, yet the report showed ending stocks, yields and production all above expectations. The changing conditions are another example of why we remain focused on equipping clients to manage their risk in any market environment."

CME Group's agriculture business reached an average daily volume of 2,022,488 contracts in the third quarter, up 18.1% year over year. In September, average daily volume reached 1,936,761 contracts, up 28.8% year over year.

In addition, Corn futures reached an average daily volume of 502,004 in the third quarter, up 35.2% year over year, and Corn options reached an average daily volume of 179,674, up 31.4% year over year.

For more information on CME Group Corn futures, please visit here.

As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.

CME-G

SOURCE CME Group

Share this article